STOCK TITAN
  1. Home
  2. Sec-filings
  3. CYBN
  4. [6-K] CYBIN INC. Current Report (Foreign Issuer)

Industry veteran Michael Cola named Cybin (CYBN) chief executive

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Cybin Inc., doing business as Helus Pharma, has appointed Michael Cola as Chief Executive Officer, effective February 10, 2026. The company highlights this leadership change as it advances a pipeline of next-generation mental health therapies toward key clinical and corporate milestones.

Cola brings more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including leading Shire’s Specialty Pharmaceutical business and serving as President and CEO of Avalo Therapeutics. He has also held senior roles at Astra-Merck, AstraZeneca, and served on boards of Phathom Pharmaceuticals and Sage Therapeutics.

Positive

  • None.

Negative

  • None.

Insights

Cybin installs a seasoned pharma executive as CEO to guide its mental health pipeline.

The company has named Michael Cola as Chief Executive Officer, effective February 10, 2026. His background spans leadership positions in central nervous system therapies, rare diseases, and specialty pharmaceuticals, which aligns with Helus’s focus on next-generation mental health treatments.

Cola previously helped build Shire’s global CNS franchise, held senior roles at Astra-Merck and AstraZeneca, led Avalo Therapeutics as President and CEO, and chaired or served on boards at Phathom Pharmaceuticals and Sage Therapeutics. Subsequent disclosures may elaborate on how this leadership translates into clinical, regulatory, and commercial progress for Helus’s pipeline.

FAQ

What is the key change disclosed in Cybin (CYBN) February 2026 Form 6-K?
Cybin Inc., operating as Helus Pharma, appointed Michael Cola as Chief Executive Officer, effective February 10, 2026. The change comes as Helus advances a pipeline of next-generation mental health therapies toward important clinical and corporate value-inflection milestones.

Who is Michael Cola, the new CEO of Cybin (CYBN)?
Michael Cola is a pharmaceutical executive with over 30 years of experience in neuroscience, rare disease, and specialty drugs. He previously led Shire’s Specialty Pharmaceutical business, served as President and CEO of Avalo Therapeutics, and held senior roles at Astra-Merck and AstraZeneca.

When did Michael Cola’s appointment as Cybin (CYBN) CEO become effective?
Michael Cola’s appointment as Chief Executive Officer became effective on February 10, 2026. The company also issued a news release on that same date through BusinessWire, describing the leadership change as Helus advances its mental health therapy pipeline toward key milestones.

What experience does Cybin’s new CEO bring to Helus Pharma?
Cybin’s new CEO brings extensive leadership experience across R&D, commercialization, corporate strategy, and capital formation. His track record includes transforming Shire into a CNS leader, guiding clinical-stage assets at Avalo Therapeutics, and serving on boards during critical clinical and commercial inflection points.

How did Cybin (CYBN) disclose the material change regarding its new CEO?
Cybin disclosed the CEO appointment through a news release disseminated via BusinessWire on February 10, 2026, and through a Material Change Report attached as Exhibit 99.1 to a Form 6-K, which is incorporated by reference into the company’s Form F-10 registration statement.

What additional background does the filing provide on Michael Cola’s education?
The filing states that Michael Cola holds a B.A. in Biology from Ursinus College and an M.S. in Biomedical Science and Engineering from Drexel University, and he studied Bioengineering at the University of Pennsylvania, where he also worked as a biomedical engineer at its affiliated hospital.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February, 2026.
Commission File Number: 001-40673


Cybin Inc.
(Exact Name of Registrant as Specified in Charter)

100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F □ Form 40-F ⊠

INCORPORATION BY REFERENCE
Exhibit 99.1 of this Form 6-K of Cybin Inc. (the "Company") is hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-292294) of the Company, as amended or supplemented.



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CYBIN INC.
(Registrant)
 
Date:February 18, 2026By:
/s/ Greg Cavers    
Name:Greg Cavers
Title:Chief Financial Officer




EXHIBIT INDEX

99.1
Material Change Report dated February 18, 2026


FORM 51-102F3
MATERIAL CHANGE REPORT
Item 1. Name and Address of Company
Cybin Inc., dba Helus Pharma (the “Company” or “Helus”)
100 King Street West, Suite 5600
Toronto, Ontario
M5X 1C9
Item 2. Date of Material Change
February 10, 2026
Item 3. News Release
A news release disclosing the material change was disseminated by the Company on February 10, 2026, through BusinessWire.
Item 4. Summary of Material Change
On February 10, 2026, the Company announced the appointment of Michael Cola as Chief Executive Officer, effective immediately.
Item 5. Full Description of Material Change
On February 10, 2026, the Company announced the appointment of Michael Cola as Chief Executive Officer, effective immediately. Mr. Cola’s appointment comes at a pivotal moment as Helus advances its pipeline of next-generation mental health therapies toward key clinical and corporate value-inflection milestones.
As President of Shire’s Specialty Pharmaceutical business, Mr. Cola helped transform the company into a global central nervous system (“CNS”) leader, launching and scaling breakthrough therapies. With more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, Mr. Cola brings deep expertise in guiding innovative CNS assets through development and into global markets, building high-performance organizations, and creating long-term shareholder value. His career spans senior leadership roles across R&D, commercialization, corporate strategy, and capital formation, positioning him to lead Helus through its next phase of growth. Earlier in his career, Mr. Cola was one of the founding hires at Merck selected to help create Astra-Merck, one of the most successful pharmaceutical spinouts, formed to commercialize Prilosec. He later held senior leadership roles at AstraZeneca PLC supporting the lifecycle expansion of Prilosec and the transition to Nexium.

More recently, Mr. Cola served as President and CEO of Avalo Therapeutics, Inc., where he led the transition to a rare disease and genomic medicine focus, licensed first-in-class clinical-stage assets, and raised significant funding. He has also served in senior board leadership roles, including as Chairman of Phathom Pharmaceuticals, Inc. and as a former board member of Sage Therapeutics, Inc., supporting organizations through clinical inflection points and commercial launches.



Mr. Cola holds a B.A. in Biology from Ursinus College, an M.S. in Biomedical Science and Engineering from Drexel University and studied Bioengineering at the University of Pennsylvania, where he also worked as a biomedical engineer at its affiliated hospital.

Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102
Not applicable.
Item 7. Omitted Information
Not applicable.
Item 8. Executive Officer
Further information regarding the matters described in this report may be obtained from Gabriel Fahel, Chief Legal Officer of the Company, who is knowledgeable about the details of the material change and may be contacted at 1-866-292-4601.
Item 9. Date of Report
February 18, 2026


Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases